Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A 52 week Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 125mcg once-daily alone and in combination with GW642444 25mcg once-daily via novel Dry Powder Inhaler (nDPI) in Subjects with Chronic Obstructive Pulmonary Disease
umeclidinium bromide/vilanterol
DB2113359
NCT01316887
Pulmonary Disease, Chronic Obstructive
Phase 3
 
November 2014

Powered by ideaPoint, Inc.